US 12297202
RIP1K inhibitors
granted A61PA61P25/00A61P29/00
Quick answer
US patent 12297202 (RIP1K inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61P, A61P25/00, A61P29/00, A61P37/00, A61P9/00